الفهرس 
Aim of the workOnly 14 pages are availabe for public view
 |  | from | 202 |  |  |
| | | from | 202 | | |
Abstract
Hepatocellular carcinoma (HCC) is ranked the fifth most common cancer and the third most common cause of cancer-related death worldwide. HCC occurs two to four times more often among men than women and within an established background of chronic liver disease. Albeit considerable advances have been made in diagnosis and treatment of HCC, it is still associated with high rate of mortality. The present study aims to estimate serum level of Golgi protein 73 and Interleukin-17 in HCC patients to assess them as markers for HCC diagnosis. Serum AFP increased significantly in HCC group as compared to both cirrhotic and control group. Serum AFP at a cut-off value of 200 (ng/ml) in HCC patients showed a sensitivity of 50%, specificity of 100%, positive predictive value of 100%, and negative predictive value of 60%. Serum Golgi protein 73 level increased significantly in HCC and cirrhotic patients as compared to control group. Serum GP73 at a cut-off 16 ng/ml in HCC patients showed sensitivity, specificity, positive predictive value, negative predictive value, 56%, 42.1%, 56%, and 42.1%, respectively. Serum interleukin-17 level increased significantly in HCC patients when compared to both cirrhotic and control groups. Serum IL-17 at a cut-off 3 pg/ml in HCC patients showed sensitivity, specificity, and positive predictive value, negative predictive value of 54%, 60.5%, 64.2%, and 50%, respectively.